NDC 72189-0334-05: MOXIFLOXACIN 5 mg/mL Solution/ Drops, 3 mL Bottle
This is a package of 3 mL of MOXIFLOXACIN 5 mg/mL Solution/ Drops from Direct Rx, first listed with the FDA Mar 2022 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 72189-334-05 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 72189 labeler · 334 product · 05 package
- Package marketed since
- Mar 8, 2022
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 7218933405 5
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 403818
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Fluoroquinolone Antibacterial class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Moxifloxacin ophthalmic solution is used to treat bacterial conjunctivitis (pink eye; infection of the membrane that covers the outside of the eyeballs and the inside of the eyelids). Moxifloxacin is in a class of antibiotics called fluoroquinolones. It works by killing the bacteria that cause infection.
Read the full MedlinePlus article ↗- It treats certain bacterial infections. The tablets and injection are used for pneumonia, skin and abdominal infections, sinus infections, bronchitis flare-ups and plague. The eye...
- Take them once a day, with or without food. Keep them at least 4 hours before or 8 hours after antacids, iron or multivitamins, since those block absorption. Take the full course y...
- The most common are nausea, diarrhea, headache and dizziness. Those are usually manageable. Call your doctor right away for tendon pain, tingling or numbness, mood or thinking chan...
- Not at the same time. Antacids with aluminum or magnesium, iron, zinc and multivitamins can keep the tablets from being absorbed. Take moxifloxacin at least 4 hours before or 8 hou...
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Moxifloxacin — tap one for details:
Moxifloxacin may be associated with lower levels of 11 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $3.70 | $11.11 / 3 ml |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 72189-0334-05 You're viewing this Main listing | 3 mL in 1 BOTTLE | 2022-03-08 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Moxifloxacin Ophthalmic Solution 5 mg/mL 00781-7135-93 | Sandoz | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin Hydrochloride 5 mg/mL 00832-1410-03 | Upsher-Smith | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin 5 mg/mL 16714-0643-01 | NorthStar | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin 5 mg/mL 60505-0582-04 | Apotex | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin ophthalmic solution 5 mg/mL 62332-0505-03 | Alembic | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin 5 mg/mL 65862-0840-03 | Aurobindo | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin 5 mg/mL 68180-0422-01 | Lupin | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin Hydrochloride 5 mg/mL 70069-0081-01 | Somerset | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin ophthalmic solution 5 mg/mL 70756-0638-25 | Lifestar | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Moxifloxacin Ophthalmic Solution 5 mg/mL 72266-0158-01 | Fosun | 1 bottle | $1.780 | AT1 | Availability likely | — |
| Vigamox 5 mg/mL 82667-0700-03 | Harrow | 1 bottle | $31.808 | AT1 | Availability likely | — |
| Moxifloxacin 5 mg/mL 68180-0421-01 | Lupin | 3 ml | $41.942 | — | FDA listed | — |
| Moxifloxacin ophthalmic solution 5 mg/mL 46708-0505-03 | Alembic | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin ophthalmic solution 5 mg/mL 50090-4781-00 | A-S | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin Ophthalmic 5 mg/mL 50090-6248-00 | A-S | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 50090-6357-00 | A-S | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 51407-0321-03 | Golden | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 67296-2129-03 | Redpharm | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin ophthalmic solution 5 mg/mL 67296-2222-03 | Redpharm | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin Hydrochloride 5 mg/mL 67296-2232-03 | Redpharm | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin Ophthalmic Solution 5 mg/mL 68083-0210-01 | Gland | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 72162-2107-02 | Bryant | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 72189-0321-05 | Direct | 3 ml | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mLthis 72189-0334-05 | Direct | 3 ml | — | — | FDA listed | — |
| Moxifloxacin Hydrochloride 5 mg/mL 76420-0331-03 | Asclemed | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 80425-0239-01 | Advanced | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 80425-0379-01 | Advanced | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 82804-0055-03 | Proficient | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 50090-8029-00 | A-S | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 67296-2348-01 | Redpharm | 1 bottle | — | AT1 | FDA listed | — |
| Moxifloxacin 5 mg/mL 85766-0312-03 | Sportpharm | 1 bottle | — | AT1 | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Moxifloxacin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII R57ZHV85D4
Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Direct Rx labeler code 72189
- Losartan Potassium and Hydrochlorothiazide 100 mg; 12.5 mg Tablet, Film Coated NDC 72189-327-30
- Pregabalin 225 mg Capsule NDC 72189-328-60
- Triamcinolone Acetonide 1 mg/g Cream NDC 72189-330-80
- Colchicine .6 mg Tablet NDC 72189-331-03
- Naproxen Sodium 550 mg Tablet NDC 72189-332-60
- Hydroxyzine Hydrochloride 10 mg Tablet NDC 72189-333-30
- KETOROLAC TROMETHAMINE 5 mg/mL Solution NDC 72189-335-05
- Diphenoxylate Hydrochloride and Atropine Sulfate 2.5 mg; .025 mg Tablet NDC 72189-336-10
- Levofloxacin 750 mg Tablet, Film Coated NDC 72189-338-05
- Oxcarbazepine 150 mg Tablet, Film Coated NDC 72189-339-60
- Quetiapine Fumarate 100 mg Tablet NDC 72189-340-30
- Rizatriptan Benzoate ODT 10 mg Tablet, Orally Disintegrating NDC 72189-341-09
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
Moxifloxacin Ophthalmic Solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infection
⏱️ Dosage and Administration ▾
Instill one drop in the affected eye 3 times a day for 7 days. Moxifloxacin is for topical ophthalmic use.
💊 Dosage Forms and Strengths ▾
Ophthalmic solution containing moxifloxacin 0.5%.
⛔ Contraindications ▾
Moxifloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.
⚠️ Warnings and Cautions ▾
5.1Hypersensitivity Reactions In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug.
Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.
5.2Growth of Resistant Organisms with Prolonged Use As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
5.3Avoidance of Contact Lens Wear Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.
🤒 Adverse Reactions ▾
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1% to 6% of patients.
Nonocular adverse events reported at a rate of 1% to 4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.
🔄 Drug Interactions ▾
Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.
👥 Use in Specific Populations ▾
8.1Pregnancy Risk Summary There are no adequate and well-controlled studies with moxifloxacin ophthalmic solution in pregnant women to inform any drug-associated risks. Oral administration of moxifloxacin to pregnant rats and monkeys and intravenously to pregnant rabbits during the period of organogenesis did not produce adverse maternal or fetal effects at clinically relevant doses. Oral administration of moxifloxacin to pregnant rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses (see DATA).
Data Animal Data Embryo-fetal studies were conducted in pregnant rats administered with 20, 100, or 500 mg/kg/day moxifloxacin by oral gavage on Gestation Days 6 to 17, to target the period of organogenesis. Decreased fetal body weight and delayed skeletal development were observed at 500 mg/kg/day [277 times the human area under the curve (AUC) at the recommended human ophthalmic dose]. The No-Observed-Adverse-Effect-Level (NOAEL) for developmental toxicity was 100 mg/kg/day (30 times the human AUC at the recommended human ophthalmic dose).
Embryo-fetal studies were conducted in pregnant rabbits administered with 2, 6.5, or 20 mg/kg/day moxifloxacin by intravenous administration on Gestation Days 6 to 20, to target the period of organogenesis. Abortions, increased incidence of fetal malformations, delayed fetal skeletal ossification, and reduced placental and fetal body weights were observed at 20 mg/kg/day (1,086 times the human AUC at the recommended human ophthalmic dose), a dose that produced maternal body weight loss and death. The NOAEL for developmental toxicity was 6.5 mg/kg/day (246 times the human AUC at the recommended human ophthalmic dose).
Pregnant cynomolgus monkeys were administered moxifloxacin at doses of 10, 30, or 100 mg/kg/day by intragastric intubation between Gestation Days 20 and 50, targeting the period of organogenesis. At the maternal toxic doses of ≥30 mg/kg/day, increased abortion, vomiting, and diarrhea were observed. Smaller fetuses/reduced fetal body weights were observed at 100 mg/kg/day (2,864 times the human AUC at the recommended human ophthalmic dose).
The NOAEL for fetal toxicity was 10 mg/kg/day (174 times the human AUC at the recommended human ophthalmic dose). In a pre- and postnatal study, rats were administered moxifloxacin by oral gavage at doses of 20, 100, and 500 mg/kg/day from Gestation Day 6 until the end of lactation. Maternal death occurred during gestation at 500 mg/kg/day.
Slight increases in the duration of pregnancy, reduced pup birth weight, and decreased prenatal and neonatal survival were observed at 500 mg/kg/day (estimated 277 times the human AUC at the recommended human ophthalmic dose). The NOAEL for pre- and postnatal development was 100 mg/kg/day (estimated 30 times the human AUC at the recommended human ophthalmic dose).
8.2Lactation Risk Summary There is no data regarding the presence of moxifloxacin ophthalmic solution in human milk, the effects on the breastfed infants, or the effects on milk production/excretion to inform risk of moxifloxacin ophthalmic solution to an infant during lactation. A study in lactating rats has shown transfer of moxifloxacin into milk following oral administration. Systemic levels of moxifloxacin following topical ocular administration are low [see Clinical Pharmacology (12.3)], and it is not known whether measurable levels of moxifloxacin would be present in maternal milk following topical ocular administration.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for moxifloxacin ophthalmic solution and any potential adverse effects on the breastfed child from moxifloxacin ophthalmic solution.
8.4Pediatric Use The safety and effectiveness of moxifloxacin ophthalmic solution have been established in all ages. Use of moxifloxacin ophthalmic solution is supported by evidence from adequate and well c… [Excerpted — this section continues on DailyMed.]
📦 How Supplied / Storage and Handling ▾
Moxifloxacin Ophthalmic Solution, USP 0.5% is supplied as a sterile ophthalmic solution in a dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package. NDC 17478-519-19 3 mL in 5 mL bottle Storage: Store at 2° to 25°C (36° to 77°F).
📋 Description ▾
Moxifloxacin Ophthalmic Solution, USP 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position. The chemical name for moxifloxacin hydrochloride 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolol[3,4-b] pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride.
The molecular formula for moxifloxacin hydrochloride is C12H24FN3O4•HCl and its molecular weight is 437.9 g/mol. The chemical structure is presented below: [Chemical Structure] Moxifloxacin hydrochloride is a slightly yellow to yellow crystalline powder. Each mL of Moxifloxacin Ophthalmic Solution, USP contains 5.45 mg moxifloxacin hydrochloride, equivalent to 5 mg moxifloxacin base.
Moxifloxacin Ophthalmic Solution contains Active: Moxifloxacin 0.5% (5 mg/mL); Inactives: Boric acid, sodium chloride, and water for injection. May also contain hydrochloric acid/sodium hydroxide to adjust pH to approximately 6.8. Moxifloxacin Ophthalmic Solution, USP is an isotonic solution with an osmolality of approximately 290 mOsm/kg.
📄 Package Label / Principal Display Panel ▾
jhoruigojfdo
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |